Navigation Links
Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:1/3/2012

n Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005

 

 

 

 


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
2. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
3. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
4. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
5. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
8. Optimer Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
10. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11. Optimer Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DUBLIN, Ohio , July 24, 2014  As part ... owners, Cardinal Health will host its annual Pharmacy Ownership Boot ... Retail Business Conference in Washington, D.C. ... pharmacists the business knowledge and confidence needed to own their ... program has become the industry,s leading event for women pharmacists ...
(Date:7/24/2014)...  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... results after market close on Thursday, July 31, 2014. ... the same day at 4:30 p.m. EDT (1:30 p.m. ... corporate update. The live call may be ...
(Date:7/24/2014)... MedVantx, Inc., the company that has ... in physician offices, MedStart Connect, today announced it ... medication non-adherence and hospital readmission rates specified in ... the Annals of Internal Medicine ... changes in generic medication pill color and shape ...
Breaking Medicine Technology:'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 3
... Mass., Aug. 31, 2011 Syndax Pharmaceuticals, Inc ... management will present at the following upcoming fall financial ... New York, NY, September 8 at 8:30 AM ET ... Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel ...
... Fla., Aug. 31, 2011 A recent study featured ... dispels the myth that physicians, offices use prostate cancer ... The article, "Utilization Trends in Prostate Cancer ... of both surgical and radiation therapy for management of ...
Cached Medicine Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences 2Study Explores Utilization Trends for Prostate Cancer Treatments 2
(Date:7/24/2014)... (PRWEB) July 24, 2014 "My child ... know until morning," said an inventor from Cynthiana, Ky. ... can cause seizures, brain damage, hearing loss, vision problems ... would have alerted me to the fever immediately." , ... to continuously monitors the child’s temperature. The unit alerts ...
(Date:7/24/2014)... drinking is associated with upsurges in hospital admissions among ... Ontario, Canada is published online today in the scientific ... of Northern British Columbia Associate Professor of Psychiatry Dr. ... Ontario over a five-year period (2002-07) involving people aged ... the week in which Ontarians turned 19 the ...
(Date:7/24/2014)... are often slow and time-consuming. Therefore, development of ... is very important for improving food safety. , ... Institute, has studied new methods of characterising Salmonella ... in water, feed and food samples. , The ... which factors in pork meat processing may contribute ...
(Date:7/24/2014)... Brightree® , the leading provider ... solutions for the post-acute care industry, announced today ... the nation’s largest family-owned providers of prosthetics, orthotics, ... as its billing and business management platform ... – including business management and document management ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 July ... $138,000 in sealant and anesthesia reversal products to ... to help save young smiles. The donation of ... and Oraverse® was distributed to America’s ToothFairy Affiliate ... with vital oral health services. The America’s ToothFairy ...
Breaking Medicine News(10 mins):Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 2Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 3Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 4Health News:Septodont Donation Helps Children in Need 2
... Investigators at Hospital for Special Surgery, collaborating with researchers ... a gene called interferon regulator factor-8 (IRF-8) is involved ... disease), rheumatoid arthritis and osteoporosis. The study, which will ... the journal Nature Medicine , could lead to ...
... , , , ... Boehringer Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation ... largest atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in ... the European Society of Cardiology Congress and published online in the ...
... , , WILMINGTON, Del., Aug. 30 ... the phase III head to head trial, PLATO (A Study of ... that ticagrelor (BRILINTA(TM)) has achieved greater efficacy in the primary endpoint, ... (9.8% vs. 11.7% at 12 months; 16% RRR; 95% CI, 0.77 ...
... watched by typical U.S. teens, analysis finds , FRIDAY, ... attract a significant proportion of teenage viewers are also ... research has found. , Using Nielsen Media Research advertising ... aired on cable TV from 2001 through 2006. The ...
... ... upheld to more stringent standards, including medical credentialing , with the influx of ... ... 29, 2009 -- According to an article from the Journal of General Internal Medicine, ...
... , ... national leader in deliciously healthy, ready to heat and eat meals, are applauding the ... weight loss is all about portion-controlled, properly balanced meals. , ... Lorton, VA (PRWEB) August 29, 2009 -- Officials at Diet-to-Go, ...
Cached Medicine News:Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 2Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 2Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 3Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 4Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 5Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 6Health News:Alcohol Ads on Cable TV Reach Young Audiences 2Health News:Alcohol Ads on Cable TV Reach Young Audiences 3Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 2Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 3Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 2Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: